Coya Therapeutics Files 8-K: Material Agreement & Equity Sales
Ticker: COYA · Form: 8-K · Filed: Oct 22, 2024 · CIK: 1835022
| Field | Detail |
|---|---|
| Company | Coya Therapeutics, Inc. (COYA) |
| Form Type | 8-K |
| Filed Date | Oct 22, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $7.25, $10.0 m, $31.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-k
TL;DR
Coya Therapeutics inked a material deal and sold some stock. Watch for updates.
AI Summary
On October 21, 2024, Coya Therapeutics, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and provided other event information. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity for Coya Therapeutics, including a new material agreement and potential dilution from equity sales, which could impact investors.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- Coya Therapeutics, Inc. (company) — Registrant
- October 21, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Coya Therapeutics?
The filing states that Coya Therapeutics, Inc. entered into a material definitive agreement on October 21, 2024, but the specific details of the agreement are not provided in this summary.
What type of equity securities were sold by Coya Therapeutics?
The filing mentions "Unregistered Sales of Equity Securities" but does not specify the type or amount of securities sold.
When was this 8-K form filed?
This 8-K form was filed on October 22, 2024.
What is Coya Therapeutics' principal executive office address?
Coya Therapeutics, Inc.'s principal executive offices are located at 5850 San Felipe St., Suite 500, Houston, Texas 77057.
What is Coya Therapeutics' telephone number?
Coya Therapeutics, Inc.'s telephone number, including area code, is (800) 587-8170.
Filing Stats: 1,372 words · 5 min read · ~5 pages · Grade level 13 · Accepted 2024-10-22 09:08:01
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share COYA The Nasdaq Stock Mar
- $7.25 — Common Stock ") at a purchase price of $7.25 per Share (the " Offering "). The Offer
- $10.0 m — roceeds to the Company of approximately $10.0 million, before deducting placement agent
- $31.0 million — quivalents (unaudited) of approximately $31.0 million. This estimate was prepared by the Comp
Filing Documents
- d877895d8k.htm (8-K) — 35KB
- d877895dex101.htm (EX-10.1) — 239KB
- d877895dex991.htm (EX-99.1) — 9KB
- 0001193125-24-240775.txt ( ) — 481KB
- coya-20241021.xsd (EX-101.SCH) — 3KB
- coya-20241021_lab.xml (EX-101.LAB) — 18KB
- coya-20241021_pre.xml (EX-101.PRE) — 11KB
- d877895d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "may," "can," "anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "seek," "estimate," "continue," "plan," "point to," "project," "predict," "could," "intend," "target," "potential," "will," or similar words and expressions of the future. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with the Company's current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of the Company's ongoing and planned clinical trials and related data, the timing of announcements, updates and results of the Company's clinical trials and related data, the Company's ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of the Company's product candidates, competitive position, industry environment, potential market opportunities, and market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company's business in general, please refer to the Company's F
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Form of Securities Purchase Agreement, by and among the Company and the Purchasers. 99.1 Press Release, dated October 22, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COYA THERAPEUTICS, INC. Date: October 22, 2024 By: /s/ Howard Berman Howard Berman Chief Executive Officer